Cargando…
Refractory right ventricular myocarditis induced by immune checkpoint inhibitor despite therapy cessation and immune suppression
BACKGROUND: Immune checkpoint inhibitors (ICIs) are currently widely used for treatment of various types of cancers. ICI-induced myocarditis, though uncommon, accounts for high risk of major adverse cardiac events and mortality, which makes appropriate diagnosis important. We here present a unique,...
Autores principales: | Mohammad, Khan O., Fanous, Hanna, Vakamudi, Sneha, Liu, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026228/ https://www.ncbi.nlm.nih.gov/pubmed/36941689 http://dx.doi.org/10.1186/s40959-023-00165-2 |
Ejemplares similares
-
Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis
por: Doms, J., et al.
Publicado: (2020) -
Immune checkpoint inhibitor–mediated myocarditis and ventricular tachycardia storm
por: McDowall, Lachlan M., et al.
Publicado: (2019) -
Immune Checkpoint Inhibitor-Associated Myocarditis With Persistent Troponin Elevation Despite Abatacept and Prolonged Immunosuppression
por: Liu, Shiying, et al.
Publicado: (2020) -
Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series
por: Zhang, Robert S., et al.
Publicado: (2021) -
Asymptomatic Immune Checkpoint Inhibitor-associated Myocarditis
por: Tanabe, Junya, et al.
Publicado: (2020)